Mechanisms underlying differential effectiveness of memantine and ketamine in rapid antidepressant responses
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Significance: Ketamine is an NMDA receptor (NMDAR) antagonist that elicits rapid antidepressant responses in patients with treatment-resistant depression. However, ketamine can also produce adverse side effects, which raised interest in whether the clinically tolerated NMDAR antagonist memantine can elicit similar fast antidepressant action. Rather surprisingly, clinical data have shown that memantine does not trigger rapid antidepressant effects for reasons that have yet to be elucidated. Here, we reconstitute the ketamine and memantine clinical findings in animal models and, combined with the analysis of synaptic function and subsequent intracellular signaling, demonstrate significant differences between the efficacies of ketamine and memantine on NMDAR-mediated neurotransmission and downstream intracellular signaling. These findings suggest a potential mechanism to explain the earlier clinical observations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This differential effect of ketamine and memantine extended to intracellular signaling coupled to spontaneous NMDA receptors, in that memantine does not inhibit eEF2K nor alter BDNF protein expression in the hippocampus, key determinants of ketamine mediated rapid antidepressant effects (Gideons et al., 2014).”
From BDNF - a key transducer of antidepressant effects (2016) · cites this paper as Gideons et al., 2014
The cited source says what the claim attributes to it.
In the citing paper
“Work done in our laboratory demonstrated that memantine has little effect on the function of NMDA receptors activated by spontaneous neurotransmitter release, in contrast to ketamine.”
From BDNF - a key transducer of antidepressant effects (2016) · cites this paper as Gideons et al., 2014
The cited source says what the claim attributes to it.
In the citing paper
“In contrast, memantine, a non-competitive NMDAR channel blocker, failed to exert antidepressant actions in animal tests 64 and in humans 65–67, and which was suggested to be because memantine does not block NMDAR-mEPSCs under physiological Mg2+ levels 64.”
From Mechanisms of ketamine action as an antidepressant (2018) · cites this paper as [64]
The cited source says what the claim attributes to it.
In the citing paper
“Importantly, ketamine’s inhibition of NMDAR-mEPSCs occurs at physiological levels of Mg2+, an effect that was associated with the rapid antidepressant behavioral actions of ketamine 64.”
From Mechanisms of ketamine action as an antidepressant (2018) · cites this paper as [64]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 1×
“The rapid antidepressant effects of ketamine have also been suggested to be mediated by mammalian target of rapamycin (mTOR)-dependent synapse formation, although it remains unclear how blockade of the NMDAR activates mTOR (30).”
BackgroundNMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926 · cited 10×
“In recent work, we demonstrated that the fast-acting antidepressant effect of ketamine requires deactivation of eukaryotic elongation factor 2 kinase (eEF2K) and subsequent desuppression of BDNF protein translation in the hippocampus (8, 9).”
BackgroundMethodResultSelf-citationMaeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103 · cited 1×
“In all experiments, we included a ketamine group as a direct comparison, which has previously been shown to elicit an antidepressant response in mice 30 min after administration without effects on locomotor activity at this time point (8, 9, 14, 15).”
MethodParsons, C. G., Danysz, W., & Quack, G. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00019-2 · Cited by 878 · cited 2×
“Pharmacol Biochem Behav 53(4): 791–797.”
BackgroundExcitatory glycine receptors containing the NR3 family of NMDA receptor subunits
Chatterton, J. E., Awobuluyi, M., Premkumar, L. S., Takahashi, H., Talantova, M., Shin, Y., Cui, J., Tu, S., Sevarino, K. A., Nakanishi, N., et al. (2002) · Nature · doi:10.1038/nature715 · Cited by 694 · cited 1×
“Additionally, it seems unlikely that any differences found between ketamine and memantine would be mediated by GluN3 containing NMDARs, because they do not show significant sensitivity to blockade by Mg or use dependent blockers (23, 24).”
BackgroundSutton, M. A., Ito, H. T., Cressy, P., Kempf, C., Woo, J. C., & Schuman, E. M. (2006) · Cell · doi:10.1016/j.cell.2006.03.040 · Cited by 633 · cited 1×
“Blockade of NMDAR-mEPSCs has been linked to the control of dendritic protein translation by decreasing calcium influx through the NMDAR into the synapse, leading to decreased phosphorylation of eEF2 by eEF2K and desuppression of protein translation (10, 12), thus providing a potential mechanism for A”
BackgroundPrice, R. B., Nock, M. K., Charney, D. S., & Mathew, S. J. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.04.029 · Cited by 600
Voltage dependence of NMDA-activated macroscopic conductances predicted by single-channel kinetics
Jahr, C., & Stevens, C. (1990) · The Journal of Neuroscience · doi:10.1523/jneurosci.10-09-03178.1990 · Cited by 564
Research works printed but not linked: 1
- 10.1124/mol.61.3.533 · doi:10.1124/mol.61.3.533 · Paper page
Cited by
Mechanisms of ketamine action as an antidepressant
Zanos, P., & Gould, T. D. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.255 · Cited by 1,127
Ketamine blocks bursting in the lateral habenula to rapidly relieve depression
Yang, Y., Cui, Y., Sang, K., Dong, Y., Ni, Z., Ma, S., & Hu, H. (2018) · Nature · doi:10.1038/nature25509 · Cited by 1,036
BDNF - a key transducer of antidepressant effects
Björkholm, C., & Monteggia, L. M. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.10.034 · Cited by 958
“receptors, in that memantine does not inhibit eEF2K nor alter BDNF protein expression in the hippocampus, key determinants of ketamine mediated rapid antidepressant effects (Gideons et al., 2014).”
BackgroundSelf-citationBDNF signaling in context: From synaptic regulation to psychiatric disorders
Wang, C. S., Kavalali, E. T., & Monteggia, L. M. (2022) · Cell · doi:10.1016/j.cell.2021.12.003 · Cited by 607
Self-citationKetamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression.
Newport, D. J., Carpenter, L. L., McDonald, W. M., Potash, J. B., Tohen, M., Nemeroff, C. B., & The APA Council of Research Task Force on Novel Biomarkers and Treatments (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15040465 · Cited by 598
Brain-Derived Neurotrophic Factor Signaling in Depression and Antidepressant Action
Castrén, E., & Monteggia, L. M. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.05.008 · Cited by 540
“The second model described above can explain why ketamine exerts antidepressant effects while memantine cannot (12).”
Self-citationThe mechanisms and functions of spontaneous neurotransmitter release
Kavalali, E. T. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3875 · Cited by 486
Self-citationTargeting glutamate signalling in depression: progress and prospects
Murrough, J. W., Abdallah, C. G., & Mathew, S. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.16 · Cited by 482
Hashimoto, K. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12902 · Cited by 335
“Although the precise mechanism(s) underlying the differences are currently unknown, the differential effects of ketamine and memantine at intracellular signaling coupled to NMDAR at rest may contribute to the difference.(145) Lanicemine (AZD6765; Ki = 0.”
BackgroundDuman, R. S., Deyama, S., & Fogaça, M. V. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.14630 · Cited by 321
Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity
Gerhard, D. M., Wohleb, E. S., & Duman, R. S. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.01.016 · Cited by 261
“A recent study links memantine’s lack of efficacy to its inability to inhibit phosphorylation of eukaryotic elongation factor 2 or increase the subsequent increase in BDNF expression, both of which occur with ketamine [64].”
BackgroundKetamine: NMDA Receptors and Beyond
Zorumski, C. F., Izumi, Y., & Mennerick, S. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.1547-16.2016 · Cited by 254
“For instance, the drug memantine is pharmacodynamically similar to ketamine but does not share strong antidepressant-like actions (Gideons et al., 2014).”
BackgroundInfluentialNitrous Oxide for Treatment-Resistant Major Depression: A Proof-of-Concept Trial
Nagele, P., Duma, A., Kopec, M., Gebara, M. A., Parsoei, A., Walker, M., Janski, A., Panagopoulos, V. N., Cristancho, P., Miller, J. P., et al. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.11.016 · Cited by 230
“The presence of extracellular magnesium may distinguish the effects of ketamine and memantine on NMDA receptors, with memantine being relatively ineffective against NMDA receptor–mediated synaptic currents in magnesium (43).”
BackgroundSustained antidepressant effect of ketamine through NMDAR trapping in the LHb
Ma, S., Chen, M., Jiang, Y., Xiang, X., Wang, S., Wu, Z., Li, S., Cui, Y., Wang, J., Zhu, Y., et al. (2023) · Nature · doi:10.1038/s41586-023-06624-1 · Cited by 204
“This suggests that a photostimulation-triggered plasticity mechanism is unlikely to contribute to the altered NMDAR-eEPSCs in the ketamine-treated groups.”
BackgroundWidman, A. J., & McMahon, L. L. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1718883115 · Cited by 204
“While there are conflicting reports on HNK’s ability to block NMDARs, it seems to enhance glutamatergic transmission mediated by AMPARs, which is required for the antidepressant-like effects in mice (19, 20, 43).”
BackgroundIadarola, N. D., Niciu, M. J., Richards, E. M., Vande Voort, J. L., Ballard, E. D., Lundin, N. B., Nugent, A. C., Machado-Vieira, R., & Zarate, C. A. (2015) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622315579059 · Cited by 201
Pham, T. H., & Gardier, A. M. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.02.017 · Cited by 186
“Moreover, both ketamine and memantine antagonize the NMDA-R at rest when Mg is absent, but only ketamine blocks the NMDA-R at rest when physiological concentrations of Mg are present (Gideons et al., 2014).”
BackgroundMethodIdentifying fast-onset antidepressants using rodent models
Ramaker, M. J., & Dulawa, S. C. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.36 · Cited by 182
Effects of a ketamine metabolite on synaptic NMDAR function
Suzuki, K., Nosyreva, E., Hunt, K. W., Kavalali, E. T., & Monteggia, L. M. (2017) · Nature · doi:10.1038/nature22084 · Cited by 180
Self-citationTargeting Homeostatic Synaptic Plasticity for Treatment of Mood Disorders
Kavalali, E. T., & Monteggia, L. M. (2020) · Neuron · doi:10.1016/j.neuron.2020.05.015 · Cited by 179
“NMDA receptor blockers such as MK-801, ketamine and memantine or the AMPA receptor blocker philanthotoxin possess this property and thus are expected to preferentially impact synapses with relatively high neurotransmitter release probability and postsynaptic channel open probability (Huettner and Bean, 1988; Gideons e…”
BackgroundSelf-citationConvergent Mechanisms Underlying Rapid Antidepressant Action
Zanos, P., Thompson, S. M., Duman, R. S., Zarate, C. A., & Gould, T. D. (2018) · CNS Drugs · doi:10.1007/s40263-018-0492-x · Cited by 171
Sanacora, G., & Schatzberg, A. F. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.261 · Cited by 160
“However, differences in half-lives and phosphorylation of eukaryotic elongation factor 2 and BDNF expression have been thought to have a role here (Gideons et al, 2014).”
BackgroundInfluentialNew targets for rapid antidepressant action
Machado-Vieira, R., Henter, I. D., & Zarate Jr., C. A. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.12.001 · Cited by 154
Role of calcium, glutamate and NMDA in major depression and therapeutic application
Deutschenbaur, L., Beck, J., Kiyhankhadiv, A., Mühlhauser, M., Borgwardt, S., Walter, M., Hasler, G., Sollberger, D., & Lang, U. E. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.02.015 · Cited by 170
Molecular and Cellular Mechanisms of Rapid-Acting Antidepressants Ketamine and Scopolamine
Wohleb, E. S., Gerhard, D., Thomas, A., & Duman, R. S. (2017) · Current Neuropharmacology · doi:10.2174/1570159x14666160309114549 · Cited by 148
Arosio, B., Guerini, F. R., Voshaar, R. C. O., & Aprahamian, I. (2021) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2021.626906 · Cited by 145
“ketamine is reinforced by the lack of the same benefit for other NMDA-R antagonists (memantine), a blunt in antidepressant action of ketamine in deletion mutant mice, and a blocked action after infusion of anti-BDNF in the medial prefrontal cortex (Autry et al., 2011; Gideons et al., 2014; Lepack et al., 2014).”
BackgroundAntidepressant actions of ketamine: from molecular mechanisms to clinical practice
Monteggia, L. M., & Zarate, C. (2015) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2014.12.004 · Cited by 149
Self-citationNeuronal correlates of depression
Chaudhury, D., Liu, H., & Han, M.-H. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2044-6 · Cited by 144
“Mechanistically, ketamine blockade of NMDA receptors deactivates CaMKII (also known as eukaryotic elongation factor 2 kinase— eEF2k) activity and the subsequent decrease in phosphorylation of eEF2 leads to rapid hippocampal BDNF synthesis by removal of baseline phosphorylated-eEF2 suppression of BDNF synthesis [48, 51…”
BackgroundSynaptic Plasticity, Metaplasticity and Depression
Vose, L. R., & Stanton, P. K. (2017) · Current Neuropharmacology · doi:10.2174/1570159x14666160202121111 · Cited by 132
“Humans and animals both exhibit reduced depression within an hour of a single dose, with improvement lasting at least 24 hr and often 1-2 weeks [32-34].”
How could stress lead to major depressive disorder?
Richter-Levin, G., & Xu, L. (2018) · IBRO Reports · doi:10.1016/j.ibror.2018.04.001 · Cited by 120
Ketamine: Mechanisms and Relevance to Treatment of Depression
Kim, J., Suzuki, K., Kavalali, E. T., & Monteggia, L. M. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-051322-120608 · Cited by 147
Self-citationThe molecular pathophysiology of depression and the new therapeutics
Tian, H., Hu, Z., Xu, J., & Wang, C. (2022) · MedComm · doi:10.1002/mco2.156 · Cited by 122
Recent insights into the mode of action of memantine and ketamine
Johnson, J. W., Glasgow, N. G., & Povysheva, N. V. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.11.006 · Cited by 116
Curcumin in Depression: Potential Mechanisms of Action and Current Evidence—A Narrative Review
Ramaholimihaso, T., Bouazzaoui, F., & Kaladjian, A. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.572533 · Cited by 134
“For instance, memantine, which is also an antagonist of NMDA receptors, after acute administration, had no effect on hippocampal BDNF and failed to show immediate antidepressant behavioral effects in an animal depression model (39).”
BackgroundHow does ketamine elicit a rapid antidepressant response?
Kavalali, E. T., & Monteggia, L. M. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.11.005 · Cited by 111
Self-citationKokkinou, M., Irvine, E. E., Bonsall, D. R., Natesan, S., Wells, L. A., Smith, M., Glegola, J. A., Paul, E. J., Tossell, K., Veronese, M., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0740-6 · Cited by 116
A Dendrite-Focused Framework for Understanding the Actions of Ketamine and Psychedelics
Savalia, N. K., Shao, L.-X., & Kwan, A. C. (2021) · Trends in Neurosciences · doi:10.1016/j.tins.2020.11.008 · Cited by 104
“Indeed, ketamine differs from other NMDAR antagonists in binding-site affinity [105], NMDAR trapping [106], potency of effect on intracellular cascades [107], and even preference for particular receptor states and subcellular locations [108].”
BackgroundCui, W., Ning, Y., Hong, W., Wang, J., Liu, Z., & Li, M. D. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1306-3 · Cited by 108
Uncoupling DAPK1 from NMDA receptor GluN2B subunit exerts rapid antidepressant-like effects
Li, S.-X., Han, Y., Xu, L.-Z., Yuan, K., Zhang, R.-X., Sun, C.-Y., Xu, D.-F., Yuan, M., Deng, J.-H., Meng, S.-Q., et al. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.85 · Cited by 98
Memantine and Ketamine Differentially Alter NMDA Receptor Desensitization
Glasgow, N. G., Povysheva, N. V., Azofeifa, A. M., & Johnson, J. W. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.1173-17.2017 · Cited by 98
“Interestingly, inclusion of extracellular Mg 2 reveals differential inhibition by memantine and ketamine of spontaneous EPSCs (i.e., activation of synaptic NMDARs; Gideons et al., 2014).”
BackgroundResultPatrizi, A., Picard, N., Simon, A. J., Gunner, G., Centofante, E., Andrews, N. A., & Fagiolini, M. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.08.018 · Cited by 100
“It is noteworthy that there are several differences in the way memantine and ketamine interact with NMDAR, including their ability to change glutamate binding at rest (69), the trapping properties of the drugs (70), and their unique effects on synaptic and extrasynaptic receptors (71).”
InfluentialA Synaptic Locus for TrkB Signaling Underlying Ketamine Rapid Antidepressant Action
Lin, P.-Y., Ma, Z. Z., Mahgoub, M., Kavalali, E. T., & Monteggia, L. M. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109513 · Cited by 99
“…N-methyl-D-aspartate (NMDA) receptor antagonist that blocks open NMDA receptor channels (Kavalali and Monteggia, 2012) rather surprisingly induces a distinctive form of synaptic plasticity in the hippocampus (Autry et al., 2011; Gideons et al., 2014; Liu et al., 2012; Nosyreva et al., 2013).”
InfluentialSelf-citationTherapeutic Modulation of Glutamate Receptors in Major Depressive Disorder
Jaso, B. A., Niciu, M. J., Iadarola, N. D., Lally, N., Richards, E. M., Park, M., Ballard, E. D., Nugent, A. C., Machado-Vieira, R., & Zarate, C. A. (2017) · Current Neuropharmacology · doi:10.2174/1570159x14666160321123221 · Cited by 98
“Recently, Gideons and colleagues investigated potential antidepressant mechanistic differences between memantine and ketamine in rodents [51].”
Antidepressant action of ketamine via mTOR is mediated by inhibition of nitrergic Rheb degradation
Harraz, M. M., Tyagi, R., Cortés, P., & Snyder, S. H. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.211 · Cited by 95
Ketamine: Neuroprotective or Neurotoxic?
Choudhury, D., Autry, A. E., Tolias, K. F., & Krishnan, V. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.672526 · Cited by 82
Holleran, K. M., Wilson, H. H., Fetterly, T. L., Bluett, R. J., Centanni, S. W., Gilfarb, R. A., Rocco, L. E. R., Patel, S., & Winder, D. G. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.3 · Cited by 86
Shen, Y., Yao, J., Jiang, X., Zhang, L., Xu, L., Feng, R., Cai, L., Liu, J., Wang, J., & Chen, W. (2015) · Human Brain Mapping · doi:10.1002/hbm.22817 · Cited by 83
“Although different drugs may trigger antidepressant responses in different ways [Gideons et al., 2014], it is notable that only baseline fMRI data were used in the current study, which were collected before and therefore independent of the heterogeneous treatment.”
BackgroundMolecular Underpinnings of Synaptic Vesicle Pool Heterogeneity
Crawford, D. C., & Kavalali, E. T. (2015) · Traffic · doi:10.1111/tra.12262 · Cited by 76
Self-citationReese, A. L., & Kavalali, E. T. (2015) · eLife · doi:10.7554/elife.09262 · Cited by 79
“DOI: 10.7554/eLife.09262 9 of 15 Gideons et al., 2014).”
BackgroundInfluentialSelf-citationAdaikkan, C., Taha, E., Barrera, I., David, O., & Rosenblum, K. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.11.028 · Cited by 76
Zhong, X., He, H., Zhang, C., Wang, Z., Jiang, M., Li, Q., Zhang, M., & Huang, X. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.05.011 · Cited by 81
Yamada, J., & Jinno, S. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107710 · Cited by 76
Memantine: Updating a rare success story in pro-cognitive therapeutics
Tari, P. K., Parsons, C. G., Collingridge, G. L., & Rammes, G. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109737 · Cited by 86
“There is evidence that high doses (50 μ M) of memantine may be less effective than ketamine at inhibiting NMDAR mEPSCs in the presence of Mg 2 + (Gideons et al., 2014).”
Rawat, R., Tunc‐Ozcan, E., McGuire, T. L., Peng, C., & Kessler, J. A. (2022) · Nature Communications · doi:10.1038/s41467-022-30386-5 · Cited by 81
NMDA Receptors Enhance Spontaneous Activity and Promote Neuronal Survival in the Developing Cochlea
Zhang-Hooks, Y.-X., Agarwal, A., Mishina, M., & Bergles, D. E. (2016) · Neuron · doi:10.1016/j.neuron.2015.12.016 · Cited by 78
“The characteristically slow kinetics of the NMDAR current was apparent after subtracting the average sEPSC in CPP from control (Figure 3C), which is comparable to NMDAR-mediated currents recorded at individual glutamatergic synapses in the CNS (Gideons et al., 2014; Goforth et al., 2011; Savi c et al., 2003).”
InfluentialDossat, A. M., Wright, K. N., Strong, C. E., & Kabbaj, M. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.11.022 · Cited by 72
“Whole cell hippocampal extracts have also been used by other investigators to examine phosphorylation of molecular targets affected by ketamine (Autry et al., 2011; Choi et al., 2015; Gideons et al., 2014; Nosyreva et al., 2013).”
Papp, M., Gruca, P., Lason-Tyburkiewicz, M., & Willner, P. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4206-0 · Cited by 68
Rapid Acting Antidepressants in Chronic Stress Models: Molecular and Cellular Mechanisms
Hare, B. D., Ghosal, S., & Duman, R. S. (2017) · Chronic Stress · doi:10.1177/2470547017697317 · Cited by 67
“This is thought to occur via inhibition of spontaneous NMDA receptor activity, which is linked to inactivation of eukaryotic elongation factor 2 (eEF2) kinase and increased BDNF protein translation.(18,68,73) Notably, eEF2 kinase knock-out animals are insensitive to the acute effects of ketamine administration.”
BackgroundSoumier, A., Carter, R. M., Schoenfeld, T. J., & Cameron, H. A. (2016) · eneuro · doi:10.1523/eneuro.0116-15.2016 · Cited by 67
“Home cage consumption was not measured in this experiment, but previous studies in rats and mice have found no effect of short-term ketamine treatment on this measure (Autry et al., 2011; Li et al., 2011; Iijima et al., 2012; Gideons et al., 2014; Nosyreva et al., 2014).”
BackgroundInhibition of the NMDA and AMPA receptor channels by antidepressants and antipsychotics
Barygin, O. I., Nagaeva, E. I., Tikhonov, D. B., Belinskaya, D. A., Vanchakova, N. P., & Shestakova, N. N. (2017) · Brain Research · doi:10.1016/j.brainres.2017.01.028 · Cited by 72
An update on NMDA antagonists in depression
Pochwat, B., Nowak, G., & Szewczyk, B. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1643237 · Cited by 70
“(2014) showed that NMDAR antagonists such as ketamine or AP-5 block NMDAR-mediated miniature excitatory postsynaptic currents at the physiological level of magnesium ions in cultured hippocampal neurons [26].”
BackgroundInfluentialPytka, K., Dziubina, A., Młyniec, K., Dziedziczak, A., Żmudzka, E., Furgała, A., Olczyk, A., Sapa, J., & Filipek, B. (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2015.10.006 · Cited by 71
Rodriguez, C. I., Wheaton, M., Zwerling, J., Steinman, S. A., Sonnenfeld, D., Galfalvy, H., & Simpson, H. B. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15l10138 · Cited by 62
Rodent ketamine depression-related research: Finding patterns in a literature of variability
Polis, A. J., Fitzgerald, P. J., Hale, P. J., & Watson, B. O. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.112153 · Cited by 67
Kokane, S. S., Armant, R. J., Bolaños-Guzmán, C. A., & Perrotti, L. I. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112548 · Cited by 61
“2014 [54] Male C57BL/6 mice (6–8 weeks) Single dose of 3 mg/kg i.”
Li, M., Xia, M., Chen, W., Wang, J., Yin, Y., Guo, C., Li, C., Tang, X., Zhao, H., Tan, Q., et al. (2019) · Translational research · doi:10.1016/j.trsl.2019.12.006 · Cited by 66
Bridging Rapid and Sustained Antidepressant Effects of Ketamine
Kim, J.-W., Suzuki, K., Kavalali, E. T., & Monteggia, L. M. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.02.003 · Cited by 59
Self-citationReese, A. L., & Kavalali, E. T. (2016) · eLife · doi:10.7554/elife.21170 · Cited by 60
“…by our group and others have shown that spontaneous neurotransmission is critical in the homeostatic regulation of synaptic strength and this regulation may have implications for the efficacy of rapidly acting antidepressants (Nosyreva et al., 2013; Gideons et al., 2014; Sutton et al., 2006).”
Self-citationZorumski, C. F., Nagele, P., Mennerick, S., & Conway, C. R. (2015) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2015.00172 · Cited by 57
“The lack of antidepressant efficacy may result from pharmacokinetic differences and/or selective effects of memantine on NMDAR channels and subtypes (92, 93).”
BackgroundRapid homeostatic plasticity and neuropsychiatric therapeutics
Kavalali, E. T., & Monteggia, L. M. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-022-01411-4 · Cited by 55
“This model does not incorporate homeostatic synaptic plasticity as a mechanism, and it is hard to reconcile with the persistent clinical observation that a closely related NMDA receptor blocker memantine does not elicit rapid antidepressant effects in the clinic despite its ability to trigger disinhibition similar to…”
BackgroundSelf-citationLv, S., Yao, K., Zhang, Y., & Zhu, S. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109378 · Cited by 61
Chronic lithium treatment elicits its antimanic effects via BDNF-TrkB dependent synaptic downscaling
Gideons, E. S., Lin, P.-Y., Mahgoub, M., Kavalali, E. T., & Monteggia, L. M. (2017) · eLife · doi:10.7554/elife.25480 · Cited by 57
“Whole-cell patch clamp recordings were performed on hippocampal pyramidal neurons as previously described (Gideons et al., 2014).”
MethodSelf-citationLavender, E., Hirasawa-Fujita, M., & Domino, E. F. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112631 · Cited by 58
Kim, J.-W., & Monteggia, L. M. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.112378 · Cited by 53
“To investigate whether the dose-dependent effect of ketamine on rapid antidepressant effects extends to intracellular signaling, we measured protein levels in the hippocampus, a brain region implicated in the antidepressant action of ketamine [11, 13, 16, 33].”
BackgroundResultSelf-citationdu Jardin, K. G., Müller, H. K., Elfving, B., Dale, E., Wegener, G., & Sanchez, C. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.05.007 · Cited by 53
“…activity in mice (Autry et al., 2011) - Unlike memantine, ketamine blocks NMDA-receptors at rest and has antidepressant-like activity in mice (Gideons et al., 2014) Offsetting of inflammatory processes implicated in depression (Erhardt et al., 2013; Hurley and Tizabi, 2013; Miller, 2013;…”
Enhanced ERK activity extends ketamine’s antidepressant effects by augmenting synaptic plasticity
Ma, Z. Z., Guzikowski, N. J., Kim, J.-W., Kavalali, E. T., & Monteggia, L. M. (2025) · Science · doi:10.1126/science.abb6748 · Cited by 50
Self-citationThe role of eEF2 kinase in the rapid antidepressant actions of ketamine
(2020) · Advances in Pharmacology · doi:10.1016/bs.apha.2020.04.005 · Cited by 52
Self-citationDifferential regulation of GluA1 expression by ketamine and memantine
Zhang, K., Yamaki, V. N., Wei, Z., Zheng, Y., & Cai, X. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.09.002 · Cited by 51
Selective molecular impairment of spontaneous neurotransmission modulates synaptic efficacy
Crawford, D. C., Ramirez, D. M. O., Trauterman, B., Monteggia, L. M., & Kavalali, E. T. (2017) · Nature Communications · doi:10.1038/ncomms14436 · Cited by 51
“Bursts of AMPA-mEPSCs were defined as groups (42) of consecutive events with inter-event intervals o40ms.”
MethodSelf-citationAge dependence of the rapid antidepressant and synaptic effects of acute NMDA receptor blockade
Nosyreva, E., Autry, A. E., Kavalali, E. T., & Monteggia, L. M. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00094 · Cited by 51
“…have been recapitulated in animal models predictive of antidepressant efficacy (Maeng et al., 2008; Li et al., 2010; Autry et al., 2011; Nosyreva et al., 2013; Gideons et al., 2014), such as the forced swim test (FST), the novelty suppressed feeding (NSF) test, and learned helplessness test.”
BackgroundSelf-citationSuzuki, K., Kim, J.-W., Nosyreva, E., Kavalali, E. T., & Monteggia, L. M. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109918 · Cited by 49
Self-citationVásquez, C. E., Riener, R. M., Reynolds, E., & Britton, G. B. (2014) · Neurochemistry International · doi:10.1016/j.neuint.2014.09.007 · Cited by 52
Mechanisms of action and clinical efficacy of NMDA receptor modulators in mood disorders
Ghasemi, M., Phillips, C., Fahimi, A., McNerney, M. W., & Salehi, A. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.07.002 · Cited by 58
“Moreover, memantine does not inhibit the phosphorylation of eEF2 or augment BDNF protein expression (Gideons et al., 2014), both of which are vital determinants of ketamine’s antidepressant efficacy.”
Multistage drug effects of ketamine in the treatment of major depression
Walter, M., Li, S., & Demenescu, L. R. (2014) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-014-0535-3 · Cited by 50
“[82] show that unlike ketamine, memantine does not inhibit the phosphorylation of eukaryotic elongation factor 2 or augment subsequent expression of BDNF, which are critical determinants of ketamine-mediated antidepressant efficacy.”
BackgroundWang, Y., Zhang, N., Liu, L., Jiang, H., Hu, D., Wang, Z., Chen, N., & Zhang, Y. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.01.024 · Cited by 52
Exploring Nitrous Oxide as Treatment of Mood Disorders: Basic Concepts
Nagele, P., Zorumski, C. F., & Conway, C. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000837 · Cited by 43
Molecular profile of dissociative drug ketamine in relation to its rapid antidepressant action
Ficek, J., Zygmunt, M., Piechota, M., Hoinkis, D., Rodriguez Parkitna, J., Przewlocki, R., & Korostynski, M. (2016) · BMC Genomics · doi:10.1186/s12864-016-2713-3 · Cited by 42
“On the other hand, memantine did not show fast antidepressant-like properties in animal models [10].”
Morgan, C. J. A., McAndrew, A., Stevens, T., Nutt, D. J., & Lawn, W. (2016) · Current Opinion in Behavioral Sciences · doi:10.1016/j.cobeha.2016.10.009 · Cited by 51
“ketamine-mediated blockade of NMDARs, triggers a sequence of intracellular signalling, the phosphorylation of eukaryotic elongation factor 2 (eEF2) that results in a de-suppression of brain derived neurotrophic factor (BDNF) translation (50-52).”
BackgroundEngaging homeostatic plasticity to treat depression
Workman, E. R., Niere, F., & Raab‐Graham, K. F. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.225 · Cited by 46
Ketamine in Major Depressive Disorder: Mechanisms and Future Perspectives
Shin, C., & Kim, Y.-K. (2020) · Psychiatry Investigation · doi:10.30773/pi.2019.0236 · Cited by 42
Novel Glutamatergic Treatments for Severe Mood Disorders
Park, M., Niciu, M. J., & Zarate, C. A. (2015) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-015-0050-5 · Cited by 40
Glutamatergic NMDA Receptor as Therapeutic Target for Depression
Réus, G. Z., Abelaira, H. M., Tuon, T., Titus, S. E., Ignácio, Z. M., Rodrigues, A. L. S., & Quevedo, J. (2015) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2015.10.003 · Cited by 49
Amidfar, M., Khiabany, M., Kohi, A., Salardini, E., Arbabi, M., Roohi Azizi, M., Zarrindast, M.-R., Mohammadinejad, P., Zeinoddini, A., & Akhondzadeh, S. (2017) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12469 · Cited by 40
“Although this special characteristic of memantine may give it a relatively modest antidepressant effect compared to other NMDA antagonists, it benefits from oral administration and, potentially, decreased dissociative and/or psychotomimetic effects and reduced abuse/diversion liability in clinical practice.(4,5,19,27,…”
ResultKetamine: The final frontier or another depressing end?
Sial, O. K., Parise, E. M., Parise, L. F., Gnecco, T., & Bolaños‐Guzmán, C. A. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112508 · Cited by 43
“Memantine, for example, does not appear to engage rapid synthesis of BDNF, which can be attributed to its lack of antidepressant efficacy in humans [262].”
BackgroundSheng, J., Shen, Y., Qin, Y., Zhang, L., Jiang, B., Li, Y., Xu, L., Chen, W., & Wang, J. (2018) · Human Brain Mapping · doi:10.1002/hbm.23976 · Cited by 42
Pazini, F. L., Rosa, J. M., Camargo, A., Fraga, D. B., Moretti, M., Siteneski, A., & Rodrigues, A. L. S. (2020) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2020.109281 · Cited by 39
A Role for Prefrontal Cortical NMDA Receptors in Murine Alcohol-Heightened Aggression
Newman, E. L., Terunuma, M., Wang, T. L., Hewage, N., Bicakci, M. B., Moss, S. J., DeBold, J. F., & Miczek, K. A. (2018) · Neuropsychopharmacology · doi:10.1038/npp.2017.253 · Cited by 38
“Interestingly, ketamine, but not memantine, can disinhibit brain-derived neurotrophic factor (BDNF) synthesis (Gideons et al, 2014).”
BackgroundFortress, A. M., Smith, I. M., & Pang, K. C. H. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.05.009 · Cited by 38
“Ketamine, a non-competitive NMDA receptor (NMDAR) antagonist, has garnered recent attention for its ability to act as a rapid antidepressant and its efficacy in treatment-resistant individuals when administered at subanesthetic doses in humans and rodents (Zarate et al., 2006; Autry et al., 2011; Gideons et al., 2014;…”
BackgroundHyperforin Potentiates Antidepressant-Like Activity of Lanicemine in Mice
Pochwat, B., Szewczyk, B., Kotarska, K., Rafało-Ulińska, A., Siwiec, M., Sowa, J. E., Tokarski, K., Siwek, A., Bouron, A., Friedland, K., et al. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00456 · Cited by 42
“Memantine and lanicemine are also not as effective as ketamine in preclinical studies (Gideons et al., 2014; Qu Y. et al., 2017).”
BackgroundNeuronal Ca2+ signalling at rest and during spontaneous neurotransmission
Kavalali, E. T. (2019) · The Journal of Physiology · doi:10.1113/jp276541 · Cited by 37
“…excitatory postsynaptic currents possess a sizable NMDA receptor-mediated component largely due to incomplete Mg2+ block, supporting NMDA receptor signalling without a strict requirement for local dendritic depolarizations (Espinosa & Kavalali, 2009, Povysheva & Johnson, 2012, Gideons et al. 2014).”
BackgroundSelf-citation
Metadata
- Authors
- Gideons, E. S., Kavalali, E. T., & Monteggia, L. M.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2014-05-27
- Volume
- 111
- Issue
- 23
- Pages
- 8649-8654
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC4060670
- OpenAlex
- W2033919519
- Cited by
- 232
- References
- 31
- Citations by year
- 2026: 6 · 2025: 16 · 2024: 15 · 2023: 13 · 2022: 14 · 2021: 16 · 2020: 24 · 2019: 20 · 2018: 23 · 2017: 21 · 2016: 29 · 2015: 24 · 2014: 11
- FWCI
- 20.59
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (MH 070727, R01MH066198, MH-066198, R01MH070727)
- National Institute of Neurological Disorders and Stroke (T32NS069562)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- ketamine, memantine, rapid antidepressant response, treatment-resistant depression, NMDA receptor antagonism, miniature excitatory postsynaptic currents, hippocampal neurons, BDNF expression, intracellular signaling, antidepressant mechanism
- MeSH terms
- Animals, Animals, Newborn, Antidepressive Agents, Cells, Cultured, Hippocampus, Humans, Ketamine, Magnesium, Male, Memantine, Mice, Inbred C57BL, Motor Activity, Neurons, Phosphorylation, Time Factors, Blotting, Western, Receptors, N-Methyl-D-Aspartate, Patch-Clamp Techniques, Excitatory Amino Acid Antagonists, Brain-Derived Neurotrophic Factor, Excitatory Postsynaptic Potentials, Peptide Elongation Factor 2, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.